Edgewise Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
EWTX Nasdaq 2830 edgewisetx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Edgewise Therapeutics, Inc.

Edgewise Therapeutics Reports Second Quarter 2026 Financial Results - Aug 6th, 2026 6:00 am
Edgewise Therapeutics (EWTX) Trades At A Rich P B, Is The Premium Justified? - Jul 21st, 2026 4:08 am
Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock? - Jul 17th, 2026 8:42 am
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business - Jul 13th, 2026 6:30 am
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline - Jul 13th, 2026 6:30 am
Podcast: Servier describes its M&A and manufacturing strategy amidst deal-making drive - Jul 7th, 2026 10:52 am
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Jul 1st, 2026 6:00 am
Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now? - Jun 29th, 2026 1:32 pm
Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data - Jun 25th, 2026 6:41 am
Edgewise Therapeutics Remains Compelling Cardiology Story Despite Atrial Fibrillation Concerns, RBC Says - Jun 17th, 2026 9:02 am
Edgewise Bounds Between Double-Digit Losses And Gain — What's Going On? - Jun 16th, 2026 2:06 pm
Edgewise Therapeutics Reports Improvements In Heart Drug Trial - Jun 16th, 2026 11:40 am
SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall - Jun 16th, 2026 6:44 am
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) - Jun 16th, 2026 5:00 am
Assessing Edgewise Therapeutics (EWTX) Valuation After A Sharp Recent Share Price Move - Jun 2nd, 2026 10:10 am
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal - Jun 2nd, 2026 9:13 am
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn - Jun 2nd, 2026 3:32 am
How Edgewise Sweetened Its Coffers By $1.55 Billion, And Removed A Key Overhang - Jun 1st, 2026 2:31 pm
EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business - Jun 1st, 2026 8:03 am
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline - Jun 1st, 2026 6:30 am